A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan

BMC Gastroenterology

Pau-Chung Chen⁶  Jau-Min Wong¹  Wen-Chao Ho⁷  Cheng-Yi Wang¹  Ming-Jium Shieh³  Jen-Shin Kuo²  Meng-Tzu Weng⁵  Chien-Chih Tung⁴  Meng-Hung Lin⁷  Shu-Chen Wei¹ 

[1] Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, 7 Chung Shan South Road, Taipei, Taiwan;Department of Internal Medicine, Kang-Ning General Hospital, Taipei, Taiwan;Department of Oncology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan;Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan;Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei, Taiwan;Department of Environmental and Occupational Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan;Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan

关键词: Nationwide;    Taiwan;    Prevalence;    Incidence;    Ulcerative colitis;    Crohn’s disease;   

Others  :  856843
DOI  :  10.1186/1471-230X-13-166

 received in 2013-08-01, accepted in 2013-11-28,  发布年份 2013

【 摘 要 】

Background

The incidence of the inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), has been increasing in Asia. We probed the nationwide registered database to assess the incidence, prevalence, gender distribution, age of diagnosis and the survival status of IBD patients in Taiwan.

Methods

A retrospective study was conducted to analyze the registered database compiled by the National Health Insurance provided by the Department of Health, Taiwan, from January 1998 through December 2008.

Results

A total of 1591 IBD patients were registered from 1998 to 2008 in Taiwan (CD: 385; UC: 1206). The incidence of CD increased from 0.19/100,000 in 1998 to 0.24/100,000 in 2008. The incidence of UC increased from 0.61/100,000 in 1998 to 0.94/100,000 in 2008. The prevalence of CD increased from 0.19/100,000 in 1998 to 1.78/100,000 in 2008. The prevalence of UC increased from 0.61/100,000 in 1998 to 7.62/100,000 in 2008. Male to female ratio for CD was 2.22 and 1.64 for UC. Age of registered for CD was predominantly between 20 to 39, and for UC between 30 to 49 years of age. The standardized mortality ratio (95% CI) was 4.97 (3.72–6.63) for CD and 1.78 (1.46–2.17) for UC, from 1998 to 2008 in Taiwan.

Conclusions

Using the Taiwan nationwide database for IBD, the incidence and prevalence of IBD in Taiwan significantly increased from 1998 to 2008. The mortality rate was higher for CD patients than UC patients, and both were higher than the general population.

【 授权许可】

   
2013 Wei et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, Chang DK, Kim JS, Song IS, Park JB, et al.: Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis 2008, 14(4):542-549.
• [2]Yang SK, Hong WS, Min YI, Kim HY, Yoo JY, Rhee PL, Rhee JC, Chang DK, Song IS, Jung SA, et al.: Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986–1997. J Gastroenterol Hepatol 2000, 15(9):1037-1042.
• [3]Yoshida Y, Murata Y: Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 1990, 74(1):67-90.
• [4]Chow DK, Leong RW, Tsoi KK, Ng SS, Leung WK, Wu JC, Wong VW, Chan FK, Sung JJ: Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol 2009, 104(3):647-654.
• [5]Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS: Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol 2002, 35(2):144-148.
• [6]Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T: Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol 2009, 44(7):659-665.
• [7]Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C: The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005, 21(4):408-413.
• [8]Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB, et al.: The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010, 25(3):453-468.
• [9]Yao T, Matsui T, Hiwatashi N: Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000, 43(10 Suppl):S85-S93.
• [10]Hsiao CH, Wei SC, Wong JM, Lai HS, Chang MH, Ni YH: Pediatric Crohn disease: clinical and genetic characteristics in Taiwan. J Pediatr Gastroenterol Nutr 2007, 44(3):342-346.
• [11]Wei SC, Ni YH, Yang HI, Su YN, Chang MC, Chang YT, Shieh MJ, Wang CY, Wong JM: A hospital-based study of clinical and genetic features of Crohn’s disease. J Formos Med Assoc 2011, 110(9):600-606.
• [12]Wei SC, Shieh MJ, Chang MC, Chang YT, Wang CY, Wong JM: Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc 2012, 75(4):151-155.
• [13]Chiu HF, Ho SC, Chen CC, Yang CY: Statin use and the risk of liver cancer: a population-based case–control study. Am J Gastroenterol 2011, 106(5):894-898.
• [14]Lai MN, Wang SM, Chen PC, Chen YY, Wang JD: Population-based case–control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010, 102(3):179-186.
• [15]Tsan YT, Lee CH, Wang JD, Chen PC: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012, 30(6):623-630.
• [16]Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC: Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012, 27(8):1266-1280.
• [17]Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, et al.: Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013, 145(1):158-165. e152
• [18]Tragnone A, Corrao G, Miglio F, Caprilli R, Lanfranchi GA: Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Int J Epidemiol 1996, 25(5):1044-1052.
• [19]Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG: Hospitalized prevalence and 5-year mortality for IBD: record linkage study. World J Gastroenterol 2010, 16(4):431-438.
• [20]Canavan C, Abrams KR, Mayberry JF: Meta-analysis: mortality in Crohn’s disease. Aliment Pharm Ther 2007, 25(8):861-870.
• [21]Doi Y, Yokoyama T, Sakai M: [Trends in mortality from intractable diseases in Japan, 1972–2004]. [Nihon koshu eisei zasshi] Japanese. J Public Health 2007, 54(10):684-694.
• [22]Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T: Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010, 16(2):347-353.
• [23]Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ: Mortality by medication use among patients with inflammatory bowel disease, 1996–2003. Gastroenterology 2007, 133(6):1779-1786.
• [24]Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P: Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007, 13(4):481-489.
• [25]Persson PG, Bernell O, Leijonmarck CE, Farahmand BY, Hellers G, Ahlbom A: Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996, 110(5):1339-1345.
• [26]Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ: Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis 2011, 17(1):471-478.
• [27]Romberg-Camps M, Kuiper E, Schouten L, Kester A, Hesselink-van de Kruijs M, Limonard C, Bos R, Goedhard J, Hameeteman W, Wolters F, et al.: Mortality in inflammatory bowel disease in the Netherlands 1991–2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis 2010, 16(8):1397-1410.
• [28]Selinger CP, Leong RW: Mortality from inflammatory bowel diseases. Inflamm Bowel Dis 2012, 18(8):1566-1572.
• [29]Travis SP: Review article: insurance risks for patients with ulcerative colitis or Crohn’s disease. Aliment Pharm Ther 1997, 11(1):51-59.
• [30]Uno H, Yao T, Matsui T, Sakurai T, Iida M, Matsumoto T, Aoyagi K, Fuchigami T: Mortality and cause of death in Japanese patients with Crohn’s disease. Dis Colon Rectum 2003, 46(10 Suppl):S15-S21.
• [31]Winther KV, Jess T, Langholz E, Munkholm P, Binder V: Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003, 125(6):1576-1582.